Anavex announces results from Phase IIb/III open-label extension trial

Anavex (AVXL) Life Sciences announced that over three years of continuous treatment with blarcamesine, ANAVEX2-73, demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. ATTENTION-AD trial result was presented at the AD/PDTM 2025 Conference. Continued blarcamesine treatment up to four years demonstrated good comparative safety profile and no associated neuroimaging adverse events. There were no deaths related to the study drug. The ATTENTION-AD trial followed the 48-week ANAVEX2-73-AD-004 double-blind clinical trial, lasting up to 192 weeks, with an open-label extension treatment duration of 96 weeks for participants in Canada and Europe and up to 144 weeks for participants in Australia to evaluate the safety and tolerability of blarcamesine and long-term effects of blarcamesine on cognition and function in participants with early Alzheimer’s disease. Blarcamesine exhibited a favorable safety profile with the majority of adverse events mild to moderate in severity, were predominantly linked to the initial titration phase, and could be managed with adjusted titration schedules.